# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cantor Fitzgerald analyst Kristen Kluska maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price tar...
B of A Securities analyst Tazeen Ahmad maintains PTC Therapeutics (NASDAQ:PTCT) with a Underperform and raises the price tar...
JP Morgan analyst Eric Joseph maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and maintains $53 price target.
PTC Therapeutics released interim results from its Phase 2 PIVOT-HD study on PTC518 for Huntington's disease. The FDA has l...
- FDA lifts PTC518 partial clinical hold based on PIVOT-HD data
Goldman Sachs analyst Paul Choi maintains PTC Therapeutics (NASDAQ:PTCT) with a Sell and raises the price target from $18 to...